Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines
1998

Combining bcl-2 Antisense Oligonucleotides with Chemotherapy for Small-Cell Lung Cancer

publication Evidence: moderate

Author Information

Author(s): U Zangemeister-Wittke, T Schenker, GH Luedke, RA Stahel

Primary Institution: University Hospital Zurich

Hypothesis

The study investigates the synergistic effects of bcl-2 antisense oligodeoxynucleotides combined with chemotherapeutic agents on small-cell lung cancer cell lines.

Conclusion

The combination of bcl-2 antisense oligodeoxynucleotide 2009 with chemotherapy agents showed synergistic cytotoxicity in small-cell lung cancer cell lines with varying levels of Bcl-2 expression.

Supporting Evidence

  • All combinations of bcl-2 antisense oligodeoxynucleotide 2009 and chemotherapeutic agents resulted in synergistic cytotoxicity in cell lines NCI-H69 and SW2.
  • The combination index for ODN 2009 and etoposide was 0.2, indicating strong synergy.
  • Cell lines with higher Bcl-2 expression showed greater sensitivity to the combination treatment.

Takeaway

Researchers found that using a special treatment that targets a cancer cell's survival protein, combined with common cancer drugs, can make the drugs work better against lung cancer cells.

Methodology

The study used small-cell lung cancer cell lines and assessed the cytotoxic effects of bcl-2 antisense oligodeoxynucleotide 2009 in combination with etoposide, doxorubicin, and cisplatin using various assays.

Limitations

The study's conclusions are limited to the specific ratios of agents used and may not apply to other combinations.

Statistical Information

P-Value

0.02

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication